trending Market Intelligence /marketintelligence/en/news-insights/trending/75x-AmOuP7zPA216dtDZLw2 content esgSubNav
In This List

Roche exercises option to develop Ionis' drug for Huntington's disease

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


Roche exercises option to develop Ionis' drug for Huntington's disease

Ionis Pharmaceuticals Inc. said Roche Holding AG exercised its option to license IONIS-HTTRx following the completion of a phase 1/2a study of the treatment in people with Huntington's disease.

Roche is taking over all development and commercial activities of the drug. Roche paid a $45 million license fee to Ionis for exercising the option. The transaction is subject to clearances under the Hart-Scott-Rodino Act.

IONIS-HTTRx is the first therapy in clinical development to target the underlying cause of Huntington's by reducing the production of the toxic mutant huntingtin protein. Huntington's disease is a rare genetic neurodegenerative disease resulting in deterioration in mental abilities and physical control. About 30,000 individuals in the U.S. have symptomatic Huntington's disease.

The safety and tolerability profile of the therapy observed in the study supports continued development. "For the first time, a drug has lowered the level of the toxic disease-causing protein in the nervous system, and the drug was safe and well tolerated," said Sarah Tabrizi, global lead investigator on the phase 1/2a study.